Venmax Drugs And Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 8.00 Cr
- Paid Up Capital ₹ 5.24 Cr
- Company Age 36 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 6.50 Cr
- Revenue Growth -20.42%
- Profit Growth -72.51%
- Ebitda -20.43%
- Net Worth -40.95%
- Total Assets -29.55%
About Venmax Drugs And Pharmaceuticals
Venmax Drugs And Pharmaceuticals Limited (VDAPL) is a Public Limited Indian Non-Government Company incorporated in India on 28 September 1988 and has a history of 36 years and four months. Its registered office is in Hyderabad, Telangana, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 531015.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 8.00 Cr and a paid-up capital of Rs 5.24 Cr.
The company has closed loans amounting to ₹6.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Venmax Drugs And Pharmaceuticals Limited India are Pratibha Jhawar as COMPANY SECRETARY and Sai Kummarikuntla as Cfo. Sadhanala Rao, Dasi Rakesh, Swapneswar Mishra, and Two other members serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
L24230TG1988PLC009102
- Company No.
009102
- Stock Symbol
BSE : 531015
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
28 Sep 1988
- Date of AGM
06 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Listed
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Venmax Drugs And Pharmaceuticals?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Pratibha Jhawar | Company Secretary | 02-Sep-2024 | Current |
| Sai Kummarikuntla | CFO | 03-Sep-2024 | Current |
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sadhanala Rao  | Additional Director | 01-Oct-2024 | Current |
| Dasi Rakesh | Additional Director | 22-Aug-2024 | Current |
| Swapneswar Mishra | Additional Director | 16-Jan-2024 | Current |
| Gundluru Reddeppa | Additional Director | 22-Aug-2024 | Current |
| Pilli Kumari | Additional Director | 16-Jan-2024 | Current |
Financial Performance of Venmax Drugs And Pharmaceuticals.
Venmax Drugs And Pharmaceuticals Limited, for the financial year ended 2016, experienced significant reduction in revenue, with a 20.42% decrease. The company also saw a substantial fall in profitability, with a 72.51% decrease in profit. The company's net worth observed a substantial decline by a decrease of 40.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Venmax Drugs And Pharmaceuticals?
In 2017, Venmax Drugs And Pharmaceuticals had a promoter holding of 23.13% and a public holding of 76.87%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Spectrogen Pharmachem LimitedGundluru Reddeppa is a mutual person
Mipco Seamless Rings Gujarat LimitedSadhanala Rao is a mutual person
- Ramya Sai Analytical Labs Private Limited
Sadhanala Rao is a mutual person
- Citrus Capital Services Private Limited
Dasi Rakesh and Swapneswar Mishra are mutual person
- Dasi Wealth Management Services Private Limited
Dasi Rakesh is a mutual person
- Blue Nile Capital Advisory Limited
Dasi Rakesh is a mutual person
Charges (Loans)
₹0
₹6.50 Cr
Charges Breakdown by Lending Institutions
- A.P. State Financial Corporation : 3.24 Cr
- Union Bank Of India : 1.50 Cr
- State Bank Of India : 1.06 Cr
- A.P. Industrial Development Corporation Ltd. : 0.70 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Jul 2008 | Union Bank Of India | ₹1.50 Cr | Satisfied |
| 17 Aug 1999 | A.P. State Financial Corporation | ₹1.43 Cr | Satisfied |
| 02 Aug 1999 | A.P. Industrial Development Corporation Ltd. | ₹7.00 M | Satisfied |
| 20 Aug 1991 | A.P. State Financial Corporation | ₹5.60 M | Satisfied |
| 13 Aug 1991 | A.P. State Financial Corporation | ₹0.62 M | Satisfied |
How Many Employees Work at Venmax Drugs And Pharmaceuticals?
Venmax Drugs And Pharmaceuticals has a workforce of 0 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Venmax Drugs And Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Venmax Drugs And Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
